

# REVIEW ON SCHIFFS BASE DERIVATIVES

**M. Sangeetha**

M. Pharm (Ph. D)

**A. Bhavana Reddy, B. Keerthi Reddy, C. Pranathi sena Reddy**

CMR COLLEGE OF PHARMACY


Kandlakoya, Medchal road, Hyderabad, 501401

**Abstract-** Researchers' interest in Schiff bases prepared from ortho-hydroxyl aromatic aldehydes is due to their ability to act as bidentate ligands for transitional metal ions. Later, in studies, it has been observed that azomethines from salicylaldehydes gave the best quantitative structure-antitumor activity relationship which has been studied for a series of Schiff bases derived from a variety of substituted aromatic amines and aldehydes (6). Schiff bases are active against many organisms such as Erysiphe graminis, Bacillus polymxa, Staphylococcus aureus, Candida albicans, Escherichia coli, Trychophytongypseum, Plasmoporaviticola, and Mycobacteria. They have shown excellent stability, and selectivity for specific metal ions such as Pb (II), Co (II), Al (III), Ag (II), Gd (III), Cu (II), Ni (II), Y(III), Zn (II), and Hg (II), so that large number of different Schiff base ligands have been used in potentiometric sensors as cation carriers. The principal interaction between the metal surface and inhibitor is Chemisorption. The inhibitor molecule should have centers that can form bonds with the metal surface by electron transfer. In such cases, the inhibitor acts as a Lewis base and the metal acts as an electrophile.


**Keywords:** schiffs base, structure activity relationship, antiviral activity, basicity

## INTRODUCTION

In the year 1864, Hugo Schiff was the first to synthesize Schiff's base under azeotropic distillation by using aldehyde or ketone and primary amine. They can be considered a sub-class of imines with the general structure  $R_1R_2C=NR'$  ( $R' \neq H$ ) (1-3). Depending on their structure, they can be considered as either secondary aldimines or secondary ketimines. When these compounds are being used as ligands to form coordination complexes with metal ions, the term Schiff base is applied. Corrin complexes occur naturally, but the majority of artificial Schiff bases are used to form many important catalysts, such as Jacobsen's catalyst. Schiff bases are imines in which  $R_3$  is an alkyl or aryl group (not hydrogen).  $R_1$  and  $R_2$  may be hydrogen. Schiff bases have a wide range of biological properties such as antimicrobial, anticancer, and antiviral. Inhibition of amyloid- $\beta$  aggregation is achieved by Schiff bases(4). They are common enzymatic intermediates where an aldehyde or ketone of a cofactor or substrate reversibly reacts with the terminal group of a lysine residue. Lysine residue forms a Schiff base with the common enzyme cofactor pyridoxal phosphate (PLP) and is transaldiminated to the substrate(s). Similarly, the cofactor retinal forms a Schiff base in human rhodopsin (via Lysine 296), which is key in the photoreception mechanism. In coordination chemistry, Schiff bases are common ligands. The ligands are derived from aromatic aldehydes and alkyl diamines(5). The imine nitrogen is basic in nature and exhibits pi-acceptor properties. In 1968, Ryōji Noyori was awarded a share of the 2001 Nobel Prize in Chemistry for the development of a copper-Schiff base complex for the metal-carbenoid cyclopropanation of styrene.



**$R_1, R_2$  and / or  $R_3$ =alkyl or aryl**





### Schiff base ligands

Researchers' interest in Schiff bases prepared from ortho-hydroxyl aromatic aldehydes is due to their ability to act as bidentate ligands for transitional metal ions. Later, in studies, it has been observed that azomethines from salicylaldehydes gave the best quantitative structure-antitumor activity relationship which has been studied for a series of Schiff bases derived from a variety of substituted aromatic amines and aldehydes<sup>(6)</sup>. Schiff bases are active against many organisms such as *Erysiphe graminis*, *Bacillus polymxa*, *Staphylococcus aureus*, *Candida albicans*, *Escherichia coli*, *Trychophytongypseum*, *Plasmoporaviticola*, and *Mycobacteria*. They have shown excellent stability, and selectivity for specific metal ions such as Pb (II), Co (II), Al (III), Ag (II), Gd (III), Cu (II), Ni (II), Y(III), Zn (II), and Hg (II), so that large number of different Schiff base ligands have been used in potentiometric sensors as cation carriers. The principal interaction between the metal surface and inhibitor is Chemisorption. The inhibitor molecule should have centers that can form bonds with the metal surface by electron transfer. In such cases, the inhibitor acts as a Lewis base and the metal acts as an electrophile. The protective compound has oxygen and nitrogen atoms with free electron pairs which are readily available for sharing and serves as a nucleophilic center. They create multiple absorption sites for the inhibitor along with the atoms of the benzene rings thus enabling stable monolayer formation<sup>(7)</sup>.

### SYNTHESIS

The first imines were synthesized in the nineteenth century by Hugo Schiff in 1864. Since then, a variety of methods have been developed for the synthesis of imines. The classical synthesis involves the condensation of a carbonyl compound with an amine under azeotropic distillation reported by Schiff. Water formed in the system was completely removed by using a molecular sieve<sup>(8)</sup>. An in-situ method for water elimination was developed using dehydrating solvents such as tetramethyl orthosilicate or trimethyl orthoformate in the 1990s. Chakraborti et al. demonstrated that the efficiency of these methods is dependent on the use of highly electrophilic carbonyl compounds and strongly nucleophilic amines. Schiff bases are often polydentate in coordinating ability, because of synthetic flexibility, the special property of C=N group and the relative ease of preparation, especially when ·SH or ·OH are present close to the azomethine group which can form a five or six membered ring with the metal ion.





### Denticity and basicity of Schiff base

The Schiff base ligands are classified according to the number of donor atoms and are named as uni-, di-, tri-, and tetra-dentate ligands. Schiff bases possess nitrogen donor atoms, so can act as bi-, tri-, tetra- or polydentate ligand. In general, the donor nature of the ligand depends both on the type of aldehyde/ketone used and the nature of primary amine/diamine.

The basicity of the Schiff base also plays a key role in the formation and stabilization of the complexes. The  $\cdot\text{OH}$  group present in the Schiff base can induce tautomerism in the compound, which leads to a compound with different structures. A large number of Schiff base compound show keto-enol tautomerism. Also, the deprotonation of alcoholic and phenolic groups is favored due to the stabilization of various oxidation states of different metal ions. Coordination with transition metal Schiff base metal complexes is prepared in situ by producing a reaction between the Schiff base and well-defined metal. This approach is clearly simple and suitable for catalytic applications. Different concentrations of different complexes can be present, when an equilibrium constant is expressed as a concentration quotient. However, the identity and homogeneity of the complex can be controlled by the introduction of a bulky group in the Schiff bases due to the shifting of the equilibrium toward the formation of a single species. A disproportionation between Schiff base metal complexes and the metal alkoxides can occur and the stability of the complexes is regulated by the equilibrium constant.

Schiff base ligands are able to coordinate many different metals with various oxidation states, enabling the use of Schiff base metal complexes for a large variety of useful catalytic transformations. Schiff-base ligands containing imidazole groups have potential donor and acceptor character in the formation of a coordination bond and function as a ligand-complex or as a self-complementary building block for the construction of the assembly structure due to the formation of a coordination bond with Cu (II) ions<sup>(9)</sup>. The versatility of Schiff base ligands and the biological, analytical, and industrial applications of their complexes have promoted further investigations in this area. The importance of Schiff base complexes for bioinorganic chemistry, biomedical applications, supramolecular chemistry, catalysis and material science, separation and encapsulation processes, and formation of compounds with unusual properties and structures has been well recognized and reviewed. A large number of Schiff bases and their complexes are of significant attention because of their biological activity including antitumor, antibacterial, fungicidal, and anticarcinogenic properties and catalytic activity<sup>(10)</sup>.

## APPLICATIONS

### Antimalarial activity

Malaria is a neglected disease that still causes serious public health problems. Every year, approximately 500 million people are afflicted by the disease, of whom around 1–3 million die, 90% of whom in sub-Saharan Africa are primarily children.<sup>[11]</sup> Malaria is currently found in more than 100 countries throughout Africa, Latin America, Asia, and Oceania. Human malaria is mainly caused by four species of Plasmodium (*P. falciparum*, *P. vivax*, *P. ovale*, and *P. malariae*). The female mosquito of the Anopheles genus is the vector of Plasmodium<sup>[12]</sup>. The search for new drugs, vaccines, and insecticides to prevent or treat this disease is clearly a priority. Schiff bases have been shown to be interesting moieties for the design of antimalarial agents. Ancistrocladidine is a secondary metabolite produced by plants from the families Ancistrocladaceae and Dioncophyllaceae that present an imine group in its molecular scaffold. Compound 1 has been shown to be active against *P. falciparum* K1 and 3D7. The minimum inhibitory concentrations (MIC values) of ancistrocladidine necessary to completely abolish *P. falciparum* K1 and 3D7 growth were 0.3 and 1.9  $\mu\text{g}/\text{mL}$ , respectively. Interestingly, compound 1 was 90- and 10-fold more selective to *P. falciparum* K1 and 3D7, respectively than to rat skeletal myoblast L-6 cells. Rathelot et al.<sup>[13]</sup> described the synthesis of Schiff base-functionalised 5-nitroisoquinolines and investigated the in vitro activity of these compounds against an ACC Niger chloroquine resistant *P. falciparum* strain. Schiff base was the most effective antimalarial agent among the synthesised 5-nitroisoquinoline derivatives. The concentration of compound 5 necessary to inhibit *P. falciparum* growth by 50% (IC<sub>50</sub>) was 0.7  $\mu\text{g}/\text{mL}$ . Under the same experimental conditions the IC<sub>50</sub> value for chloroquine was 0.1  $\mu\text{g}/\text{mL}$ <sup>[13]</sup>

### Antibacterial activity

The increase in the mortality rate associated with infectious diseases is directly related to bacteria that exhibit multiple resistance to antibiotics. The lack of effective treatments is the main cause of this problem<sup>[14,15]</sup>. The development of new antibacterial agents with novel and more efficient mechanisms of action is definitely an urgent medical need<sup>[16]</sup>. Schiff bases have been pointed to as promising antibacterial agents. For example, N-(salicylidene)-2-hydroxyaniline is effective against Mycobacterium

tuberculosis H37Rv, exhibiting an MIC value of 8 lg/mL. The selectivity of compound 4 was checked by performing experiments with J774 macrophages. No cytotoxic effect on J774 macrophages was observed for compound 4, even when it was tested at concentrations as high as 1000 lg/mL. More than 80% of macrophage cells were viable at such experimental conditions, demonstrating the high selectivity of compound 4. The synthesis and antimicrobial activity of a series of Schiff bases derived from the condensation of 5-chloro-salicylaldehyde and primary amines has recently been reported.<sup>[17]</sup> The 5-chloro-salicylaldehyde-Schiff base derivatives were most active against at least one of the evaluated bacterial species. *Pseudomonas fluorescens* was the strain most sensitive to compounds 6–11 and 13–15, with MIC values ranging from 2.5 to 5.2 lg/mL. The MIC value for the reference drug kanamycin against the same bacterial strain was 3.9 lg/mL. The Schiff bases 6, 7, 9–11, 14, and 15 presented MIC values in the range of 1.6–5.7 lg/mL against *Escherichia coli*, while the MIC value for kanamycin was 3.9 lg/mL. *Bacillus subtilis* was sensitive to the Schiff base 14 only (MIC = 1.8 lg/mL). The MIC values for compounds 6 and 7 against *Staphylococcus aureus* were, respectively, 3.1 and 1.6 lg/mL.<sup>[17]</sup> Isatin-derived Schiff bases have also been reported to possess antibacterial activity.<sup>[18]</sup> Twenty-eight bacteria of clinical interest were used in the studies performed by Pandeya and colleagues. The authors disclosed the isatin-derived Schiff base 16 (Fig. 3) as the most potent compound amongst those synthesised against all the pathogenic bacteria studied. The MIC values for compound 16 against *E. coli* NCTC 10418, *Vibrio cholerae* non-01, *Enterococcus faecalis*, *Proteus shigelloides* were 2.4, 0.3, 1.2, and 4.9 lg/mL, respectively, while the MIC values for sulfamethoxazole (reference drug) against the same bacterial strains were in the range of 312–5000 lg/mL. Thus compound 16 was notably 1040-, 1040-, 4160-, and 1020-fold more potent than sulphamethoxazole. Other isatin-derived Schiff bases have been described in the literature, but with no expressive antibacterial activities.<sup>[19,20]</sup> The isoniazid-derived Schiff base 17 was active against *M. tuberculosis* H37Rv, exhibiting an MIC value of 0.03 mg/L.<sup>[21]</sup> In this respect, compound 17 was slightly more potent than isoniazid, its immediate synthetic precursor. Additionally, the isoniazid-derived Schiff base 17 was not toxic against the cell line VERO (epithelial cells from healthy monkey kidney). The IC<sub>50</sub> for compound 17 against VERO cells was as high as 1 g/mL, indicating that this isoniazid-derived Schiff base is selective for bacterial cells. The therapeutic safety and effectiveness for compound 17 is higher than 40,000, making this Schiff base an excellent lead for the development of anti-tubercular agents.<sup>[21]</sup> In 2005, Panneerselvam et al. described the synthesis and in vitro antibacterial activity of eleven morpholine-derived Schiff bases. Shows the chemical structure of three of them (compounds 18–20). The authors found that *S. aureus*, *Micrococcus luteus* were the bacteria most sensitive to the morpholine-derived Schiff base 18 (MIC = 20 and 32 lg/mL, respectively). *Streptococcus epidermidis* was more sensitive to the morpholine-derived Schiff base 19 (MIC = 17 lg/mL) and *Bacillus cereus* and *E. coli* were more sensitive to compound 20 (MIC = 21 and 16 lg/mL, respectively). Schiff bases with a 2,4-dichloro-5-fluorophenyl moiety are also effective in the inhibition of bacterial growth. Schiff bases from this class completely inhibited the growth of *S. aureus*, *E. coli*, *Pseudomonas aeruginosa*, and *Klebsiella pneumoniae*. MIC values for these compounds varied from 6.3 to 12.5 lg/mL, which are comparable to those obtained for the reference drug ciprofloxacin.<sup>[22]</sup> Madurahydroxy lactone Schiff bases are imines derived from natural products. Madurahydroxylactones are secondary metabolites produced by the plant *Actinomyces rubra*.<sup>[23]</sup> The imines 25–30 are examples of Schiff bases belonging to this class. With the exception of compounds 25 and 30, all Madurahydroxylactone-derived compounds were effective in the in vitro inhibition of *B. subtilis*, *Micrococcus flavus*, *Sarcina lutea*, and *S. aureus* growth, with MIC values varying from 0.2 to 3.1 lg/mL.<sup>[24]</sup> These same compounds (26–29) presented very low activity against *Mycobacterium phlei* or *Proteus vulgaris* (MIC values higher than >50.0 lg/mL).<sup>[24]</sup> Other molecules of natural or non-natural origin that are platforms for the synthesis of Schiff bases for antibacterial activities include amino acids, coumarins, sulfonamides, or resacetophenones, aminothiazolyl bromocoumarins, crown ethers, O-phthaldehyde, or 2-aminophenol and 1,2,4-triazoles.<sup>[25,31]</sup> The antibacterial property of compounds representative of these classes was examined. However, they did not exhibit any notable activity.

### Antifungal activity

Fungal infections are not usually limited to the superficial tissues; indeed, a significant increase in life-threatening systemic fungal infections has been reported.<sup>[32]</sup> The fundamental reason for this is the increasing number of patients at risk, including those with advanced age, major surgery, immunosuppressive therapy, acquired immunodeficiency syndrome (AIDS), cancer treatment, and solid-organ and hematopoietic stem cell transplantation.<sup>[33]</sup> The search and development of more effective antifungal agents are mandatory.<sup>[34,35]</sup> and some Schiff bases are known to be promising antifungal agents. *Alternaria brassicae* and *Alternaria brassicicola* are phytopathogenic fungi that severely affect the production of most cruciferous crops (broccoli, cauliflower, mustard, turnip, cabbage, rape, and radish). N-(Salicylidene)-2-hydroxyaniline 4 (Fig. 2) at the concentration of 500 ppm inhibited the growth of these fungi by 67–68%.<sup>[36]</sup> Compounds 2 and 3 are examples of chitosan-derived Schiff bases with antifungal activity. They inhibited the growth of *Botrytis cinerea* and *Colletotrichum lagenarium* by 26–33% and 35–38% when used at 1000 ppm, respectively.<sup>[36]</sup> Overall, studies evaluating the effect of Schiff bases on phytopathogenic fungal growth have been modest and deserve more investigation. Schiff bases with a 2,4-dichloro-5-fluorophenyl moiety, such as compounds 21 and 31–34 have been demonstrated to inhibit the growth of fungi of clinical interest, such as *Aspergillus fumigatus*, *Aspergillus flavus*, *Trichophyton mentagrophytes*, and *Penicillium marneffei*. The MIC values for these compounds were in the range of 6.3–12.5 lg/mL, indicating that they are as potent as the reference fluconazole.<sup>[22]</sup> Piperonyl-derived Schiff bases were active against some fungi at micromolar concentrations. They inhibited the growth of *Trichophyton rubrum* (MIC = 820–980 μM) and *Epidermophyton floccosum* (MIC = 200–930 μM).<sup>[37]</sup> The isatin-derived Schiff bases 41–51 were considerably active against *Microsporum audouinii* (MIC values ranging from 2.4 to 9.7 lg/mL) and *Microsporum gypseum* (MIC values ranging from 1.2 to 9.7 lg/mL). Compounds 16 and 41–51 also inhibited the growth of *Candida albicans*, *Aspergillus niger*, *Cryptococcus neoformans*, *T. mentagrophytes*, *E. floccosum*, and *Histoplasma capsulatum* at MIC values higher than 10 lg/mL and lower than 79 lg/mL. In another study, Panneerselvam et al. showed that the growth of both *C. albicans* and *A. niger* was compromised by treatment with compound 20 at 20 lg/mL or compound 52 at 30 lg/mL. As for antibacterial activity, natural product-derived Schiff bases are also promising for the design of new antifungal agents. Domb and colleagues have described an interesting approach to synthesize a nystatin-dextran-derived Schiff base. This approach



dramatically improved nystatin solubility in water [37]. Compound 53 completely inhibited the growth of *C. albicans* and *C. neoformans* at 20 µg/mL, while a concentration of 10 µg/mL was required for free nystatin to have a similar effect. Although the nystatin-dextran-derived Schiff base 53 was less active than nystatin itself, the former was shown to be much less toxic to normal cells [37].

### Antiviral activity

The use of vaccines may lead to the eradication of viral pathogens, such as smallpox, polio, and rubella. However, virus-related and hepatitis C human immunodeficiency diseases have been the drawback of vaccine approaches [38]. Viral diseases are life-threatening for immunocompromised patients and a prompt treatment is required to overcome this problem. Although there are many therapeutic options for viral infections, currently available antiviral agents are not yet fully effective, probably due to the high rate of virus mutation. They may also present any of a number of side effects. Salicylaldehyde Schiff bases of 1-amino-3-hydroxyguanidine tosylate are a good platform for the design of new antiviral agents [39,40]. In fact, from a set of different 1-amino-3-hydroxyguanidine tosylate-derived Schiff bases, compound 54 was shown to be very effective against mouse hepatitis virus (MHV), inhibiting its growth by 50% when employed at concentrations as low as 3.2 µM [40]. Recently, Sriram and colleagues reported [40] the synthesis and antiviral activity of the abacavir-derived Schiff bases 55–65. These compounds are a new series of abacavir prodrugs. Abacavir is a nucleoside analogue capable of inhibiting the activity of reverse transcriptase. It is used to treat human immunodeficiency virus (HIV) and AIDS, and is available under the trade name Ziagen (GlaxoSmithKline). Compounds 55–65 were significantly effective against the human immunodeficiency virus-type 1 (HIV-1). The effective concentration (EC<sub>50</sub>) of these abacavir-derived Schiff bases necessary to achieve 50% protection of human leukemic cells (CEM) against the cytopathic effect of HIV-1 was lower than 6 µM [40]. Notably, compound 57 was the most potent Schiff base, being effective at 50 nM. This compound is only toxic to CEM cells at concentrations higher than 100 µM, indicating its potential as a lead compound for the design of anti-HIV [41].

### REFERENCES:

- IUPAC, editor. Compendium of Chemical Terminology. 2nd ed. IUPAC; Wiley-Blackwell. 11 August 1997
- Schiff H. Mitteilungen aus dem Universitätslaboratorium in Pisa. 2. Eine neue Reihe organischer Basen [Communications from the university laboratory in Pisa: 2. A new series of organic bases]. *Annalen der Chemie und Pharmacie* (in German). 1864; 131:118-119. DOI: 10.1002/jlac.18641310113
- Schiff U. Sopra una nova serie di basi organiche [On a new series of organic bases]. *Giornale di Scienze Naturali ed Economiche* (in Italian). 1866; 2:201-257
- Bajema EA, Roberts KF, Meade TJ. Chapter 11. Cobalt-Schiff Base complexes: Preclinical research and potential therapeutic uses. In: Sigel A, Freisinger E, Sigel RKO, Carver PL, editors. *Essential Metals in Medicine: Therapeutic Use and Toxicity of Metal Ions in the Clinic*. Berlin: de Gruyter GmbH; 2019. pp. 267-301
- Hernández-Molina R, Mederos A. Acyclic and macrocyclic Schiff Base ligands. *Comprehensive Coordination Chemistry*. 2003; II:411-446
- Hodnett EM, Dunn WJ. *Journal of Medicinal Chemistry*. 1970; 13:768
- Quan Z, Chen S, Li Y. *Corrosion Science*. 2001; 43:1071
- Taguchi K, Westheimer FH. *The Journal of Organic Chemistry*. 1971; 36:1570
- Chakraborti AK, Bhagat S, Rudrawar S. *Tetrahedron Letters*. 2004; 45:7641
- Ren S, Wang R, Komatsu K, Bonaz-Krause P, Zyrianov Y, McKenna CE, et al. *Journal of Medical Chemistry*. 2002; 45:410
- Bohach GA, Fast DJ, Nelson RD, Schlievert PM. Malaria. In: Rodes J, Benhamou JP, Blei A, Reichen J, Rizzetto M, editors. *The textbook of hepatology: from basic science to clinical practice*. Oxford (UK): Wiley Blackwell; 2007. p. 1029–34.
- Kayser O, Kiderlen AF, Croft SL. Natural products as potential antiparasitic drugs. *Parasitol Res* 2003;90(Suppl 2):S55–62.
- Rathelot P, Vanelle P, Gasquet M, Delmas F, Crozet MP, Timon-David P, et al. Synthesis of novel functionalized 5-nitroisoquinolines and evaluation of in vitro antimalarial activity. *Eur J Med Chem* 1995;30(6):503–8.
- Baquero F. Gram-positive resistance: challenge for the development of new antibiotics. *J Antimicrob Chemother* 1997;39(Suppl.A):1–6.
- Alekshun MN, Levy SB. Molecular mechanisms of antibacterial multidrug resistance. *Cell* 2007;128(6):1037–50.
- Rice LB. Unmet medical needs in antibacterial therapy. *Biochem Pharmacol* 2006;71(7):991–5.
- Shi L, Ge HM, Tan SH, Li HQ, Song YC, Zhu HL, et al. Synthesis and antimicrobial activities of Schiff bases derived from 5-chloro-salicylaldehyde. *Eur J Med Chem* 2007;42(4):558–64.
- Pandeya SN, Sriram D, Nath G, de Clercq E. Synthesis and antimicrobial activity of Schiff and Mannich bases of isatin and its derivatives with pyrimidine. *IL Farmaco* 1999;54(9):624–8.
- Pandeya SN, Sriram D, Nath G, de Clercq E. Synthesis, antibacterial, antifungal and anti-HIV activities of Schiff and Mannich bases derived from isatin derivatives and N-[4-(4-chlorophenyl)thiazol-2-yl] thiosemicarbazide. *Eur J Pharm Sci* 1999;9(1):25–31.
- Jarrahpour A, Khalili D, de Clercq E, Salmi C, Brunel JM. Synthesis, antibacterial, antifungal and antiviral activity evaluation of some new bis-Schiff bases of isatin and their derivatives. *Molecules* 2007;12(8):1720–30.
- Hearn MJ, Cynamon MH. Design and synthesis of antituberculars: preparation and evaluation against *Mycobacterium tuberculosis* of an isoniazid Schiff base. *J Antimicrob Chemother* 2004;53(2):185–91.

22. Karthikeyan MS, Prasad DJ, Poojary B, Bhat KS, Holla BS, Kumari NS. Synthesis and biological activity of Schiff and Mannich bases bearing 2,4-dichloro-5-fluorophenyl moiety. *Bioorg Med Chem* 2006;14(22):7482–9.
23. Paulus EF, Dornberger K, Werner W, Fenske D. Madurahydroxylactone. *Acta Crystallogr* 1994;50(12):2064–7.
24. Heinisch L, Roemer E, Jutten P, Haas W, Werner W, Mollmann U. Semisynthetic derivatives of madurahydroxylactone and their antibacterial activities. *J Antibiot (Tokyo)* 1999;52(11):1029–41.
25. Chohan ZH, Arif M, Sarfraz M. Metal-based antibacterial and antifungal amino acid derived Schiff bases: their synthesis, characterization and in vitro biological activity. *Appl Organomet Chem* 2007;21(4):294–302.
26. Baluja S, Solanki A, Kachhadia N. Evaluation of biological activities of some Schiff bases and metal complexes. *J Iran Chem Soc* 2006;3(4):312–7.
27. Venugopala KN, Jayashree BS. Microwave-induced synthesis of Schiff bases of aminothiazolyl bromocoumarins as antibacterials. *Indian J Pharm Sci* 2008;70(1):88–91.
28. Yildiz M, Kiraz A, Duğer B. Synthesis and antimicrobial activity of new crown ethers of Schiff base type. *J Serb Chem Soc* 2007;72(3):215–24.
29. Abdallah SM, Mohamed GG, Zayed MA, El-Ela MSA. Spectroscopic study of molecular structures of novel Schiff base derived from O-phthaldehyde and 2-aminophenol and its coordination compounds together with their biological activity. *Spectrochim Acta Part A: Mol Biomol Spectrosc* 2009;73(5):833–40.
30. T'ang A, Lien EJ, Lai MMC. Optimization of the Schiff bases of N-hydroxy-N'-aminoguanidine as anticancer and antiviral agents. *J Med Chem* 1985;28(8):1103–6.
31. Bayrak H, Demirbas A, Karaoglu SA, Demirbas N. Synthesis of some new 1,2,4-triazoles, their Mannich and Schiff bases and evaluation of their antimicrobial activities. *Eur J Med Chem* 2009;44(3):1057–66.
32. Sundriyal S, Sharma RK, Jain R. Current advances in antifungal targets and drug development. *Curr Med Chem* 2006;13(11):1321–35.
33. Nucci M, Marr KA. Emerging fungal diseases. *Clin Infect Dis* 2005;41(4):521–6.
34. Martins CVB, da Silva DL, Neres ATM, Magalhães TFF, Watanabe GA, Modolo LV, et al. Curcumin as a promising antifungal of clinical interest. *J Antimicrob Chemother* 2009;63(2):337–9.
35. Martins CVB, de Resende MA, da Silva DL, Magalhães TFF, Modolo LV, Pilli RA, et al. In vitro studies of antifungal activity of goniothalamin enantiomers. *J Appl Microbiol* 2009;107(4):1279–86.
36. Rehman W, Baloch MK, Muhammad B, Badshah A, Khan KM. Characteristic spectral studies and in vitro antifungal activity of some Schiff bases and their organotin (IV) complexes. *Chin Sci Bull* 2004;49(2):119–22.
37. Echevarria A, Nascimento MG, Geronimo V, Miller J, Giesbrecht A. NMR spectroscopy, Hammett correlations and biological activity of some Schiff bases derived from piperonal. *J Braz Chem Soc* 1999;10(1):60–4.
38. Domb AJ, Linden G, Polachek I, Benita S. Nystatin-dextran conjugates: synthesis and characterization. *J Polym Sci Part A: Polym Chem* 1996;34(7):1229–36.
39. de Clercq E. Strategies in the design of antiviral drugs. *Nat Rev Drug Discov* 2002;1:13–25.
40. Wang PH, Keck JG, Lien EJ, Lai MMC. Design, synthesis, testing and quantitative structure–activity relationship analysis of substituted salicylaldehyde Schiff bases of 1-amino-3-hydroxyguanidine tosylate as new antiviral agents against coronavirus. *J Med Chem* 1990;33(2):608–14.
41. Sriram D, Yogeewari P, Myneedu NS, Saraswat V. Abacavir prodrugs: microwave-assisted synthesis and their evaluation of anti-HIV activities. *Bioorg Med Chem Lett* 2006;16(8):2127–9.